GUANGZHOU, China, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR) (the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced the resignation of Mr. Leo Li as a director from the Company’s board of directors (the “Board”) and as the Company’s chief financial officer, effective September 27, 2024.  Mr. Li has confirmed that his resignation was for personal reasons and n ...

GUANGZHOU, China, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2024. Recent Business Updates Therapy Selection Presented study results on small-cell lung cancer and colorectal cancer at the ASCO in June 2024. “The efficacy and safety of high d ...

GUANGZHOU, China, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (the “Company” or “Burning Rock”) announces that, on August 19, 2024, it intends to submit requests (a) to the London Stock Exchange (the “LSE”), to cancel the admission to trading on the Main Market of its American Depositary Shares representing the class A ordinary shares of the Company (the “ADSs”), and (b) to the UK Financial Conduct Authority, to cancel the listing of the ADSs on the Official List. As a result of sustained ...

GUANGZHOU, China, June 03, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it has received a notification letter from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“NASDAQ”) on May 30, 2024, informing the Company that it has regained compliance with the minimum bid p ...

GUANGZHOU, China, May 30, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))) has recently announced a collaboration with Bayer to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx), aiming to provide diagnostic methods, to enable treatment choice for patients with cancer in China, while driving innovation and development in cancer therapy. This collaboration will focus on the development of companion diagnostic products in Chin ...

文章核心观点 - 公司与拜耳合作开发基于下一代测序(NGS)的伴随诊断试剂(CDx),旨在为中国癌症患者提供诊断方法,以支持精准治疗选择 [1][2] - 该合作将专注于在中国开发伴随诊断产品,共同开发针对拜耳精准癌症疗法的NGS-based CDx [1] - 公司致力于全球范围内伴随诊断的综合开发,并希望通过整合双方在癌症诊断和治疗领域的资源与专业知识,为精准诊断的联合开发树立标准和高质量的典范 [2] - 公司旨在为患者提供更有效的治疗选择,为医疗领域树立新的标杆 [2] 公司概况 - 公司专注于将NGS技术应用于精准肿瘤学领域,主要业务包括:1)为晚期癌症患者提供NGS疗法选择检测;2)为制药公司提供生物标志物检测和伴随诊断开发的全球服务;3)早期癌症筛查 [3]

财务数据和关键指标变化 - 公司在Q1 2024实现了商业层面的盈亏平衡,这是公司连续两年努力提高盈利能力的成果 [10][20][21] - 销售和营销费用占收入的比例降至35%,创历史新低,体现了公司销售效率的提升 [13] - 毛利率方面,公司在前几个季度已经取得进展,本季度没有重大更新 [14] - 管理费用大幅下降,主要得益于之前裁员和减少办公场地等措施 [15] - 公司Q1现金余额为5.73亿人民币,预计2024年全年现金流出将在1.5-2亿人民币之间,未来2-3年内有充足的现金储备 [16][17] 各条业务线数据和关键指标变化 - 公司正加快从中央实验室向医院内部转型,Q1医院内部业务收入首次超过中央实验室 [18][19] - 医院内部业务收入同比和环比均有增长,是公司未来收入增长的主要驱动力 [19] - 总体收入环比增长4%,主要得益于医院内部业务的增长 [20] 各个市场数据和关键指标变化 - 无相关内容 公司战略和发展方向及行业竞争 - 公司正在努力提高盈利能力,未来将继续推进向盈利的转型 [10][20][21] - 公司正加快从中央实验室向医院内部转型,这是公司的长期战略 [18][19] 管理层对经营环境和未来前景的评论 - 公司表示,经过2023年下半年的行业波动,目前情况已经恢复正常 [10] - 公司对未来前景持乐观态度,预计2024年全年实现非公认会计准则下的毛利润扣除管理费用的盈亏平衡 [21] 其他重要信息 - 无相关内容 问答环节重要的提问和回答 无相关内容

Burning Rock Biotech Limited 1Q 2024 results 29 May 2024 Disclaimer This presentation has been prepared by Burning Rock Biotech Limited (the "Company") solely for information purpose and has not been independently verified. No representations, warranties or undertakings, express or implied, are made by the Company or any of its affiliates, advisers, or representatives as to, and no reliance should be placed upon, the accuracy, fairness, completeness or correctness of the information or opinions presented or ...

Exhibit 99.1 Burning Rock Reports First Quarter 2024 Financial Results GUANGZHOU, China, May 29, 2024—Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the "Company" or "Burning Rock"), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2024. Recent Business Updates • Early Detection • THUNDER study for 6-cancer test was included in the Diagnosis and Treatment Guid ...